Condition
Non-metastatic Castration-resistant Prostate Cancer clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Non-metastatic Castration-resistant Prostate Cancer clinical trials that are recruiting, at sites in 4 countries (most in South Korea (1), Germany (1), China (1)). By phase: Phase 4 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 4Countries
Newest Non-metastatic Castration-resistant Prostate Cancer clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Darolutamide plus ADT for men with non-metastatic prostate cancer that progressed after prior ADT+bicalutamide | — | Multiple Locations | Recruiting | Apr 20, 2026 |
| Registry for prostate cancer treatment and outcomes | — | Freiburg im Breisgau, Baden-Wurttemberg and 52 other locations | Recruiting | Feb 19, 2025 |
| Observing the safety of darolutamide in Korean men with prostate cancer | — | Many Locations | Recruiting | Mar 27, 2024 |
| Evaluating the safety and effectiveness of Darolutamide with standard hormone therapy for prostate cancer | Phase 4 | Nadiād, Gujarat and 14 other locations | Recruiting | Apr 27, 2022 |
All recruiting trials (4)
-
Darolutamide plus ADT for men with non-metastatic prostate cancer that progressed after prior ADT+bicalutamide
This study tests whether adding darolutamide to ongoing androgen deprivation therapy helps men with non-metastatic castration-resistant prostate cancer who previously progressed on bicalutamide plus ADT.
-
Registry for prostate cancer treatment and outcomes
This study is tracking the treatment and progress of men with recurrent and advanced prostate cancer to see how different therapies affect their lives over time.
-
Observing the safety of darolutamide in Korean men with prostate cancer
This study is testing the safety of darolutamide in Korean men with prostate cancer to see how well it works as part of their regular treatment.
-
Evaluating the safety and effectiveness of Darolutamide with standard hormone therapy for prostate cancer
This study is testing if adding Darolutamide to standard hormone therapy can help men with high-risk prostate cancer that keeps progressing even when testosterone is low.
Related topics
Quick answers
How many Non-metastatic Castration-resistant Prostate Cancer clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in South Korea (1 trial), Germany (1 trial), China (1 trial), India (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.